Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Study of ASTX727 vs IV Decitabine in MDS CMML and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727

ringed sideroblasts
conjugated bilirubin
secondary acute myeloid leukemia
astx727
blast cells
  • 269 views
  • 27 Jan, 2021
  • 93 locations
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with IPSS risk category of low

blood transfusion
decitabine
  • 26 views
  • 12 Sep, 2021
  • 25 locations
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

  • 3 views
  • 25 Jan, 2021
Venetoclax and ASTX727 for the Treatment of Relapsed Refractory or Newly Diagnosed Acute Myeloid Leukemia

This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment

  • 0 views
  • 15 Mar, 2021
  • 1 location
Pharmacokinetics Safety and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

This is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and preliminary efficacy of ASTX727 when given in

venetoclax
decitabine
carbon monoxide
induction chemotherapy
ejection fraction
  • 0 views
  • 11 Aug, 2021
  • 7 locations
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs

  • 0 views
  • 27 Jun, 2021
  • 7 locations
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

This is a non-randomized, open-label, Phase IbI study to assess the safety and efficacy of oral decitabine (ASTX727) and durvalumab (MEDI4736) combination therapy in the treatment of patients

squamous cell carcinoma of head and neck
dental caries
durvalumab
neutrophil count
carcinoma
  • 15 views
  • 27 Jan, 2021
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable

  • 0 views
  • 22 Sep, 2021
  • 22 locations
ASTX727 Venetoclax and Gilteritinib for the Treatment of Newly Diagnosed Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib in treating patients with FLT3

gilbert's syndrome
hydroxyurea
ejection fraction
serum bilirubin level
venetoclax
  • 0 views
  • 25 Aug, 2021
  • 1 location
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome

decitabine
leukemia
myelomonocytic leukemia
hydroxyurea
chronic myelomonocytic leukemia
  • 0 views
  • 17 Sep, 2021
  • 1 location